Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anton Dias Perera

Vascular Surgery Germantown, TN Medical Doctor

NPI 1336313170 CMS profile 60078

1385 W Brierbrook Rd, Germantown, TN 38138

Open in the dashboard

General payments

$831,792

372 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anton Dias Perera of Germantown, TN is reported in the CMS Open Payments database as having received $831,792 across 372 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,008 34
2024 General $821,081 125
2023 General $1,563 42
2022 General $1,420 34
2021 General $413 12
2020 General $1,272 59
2019 General $4,035 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anton Dias Perera
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Anton Dias Perera were reported at $2,008. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Anton Dias Perera Vascular Surgery median Middle half National median
2019 $4,035 $796 $226–$2,363 $163
2020 $1,272 $348 $118–$1,110 $114
2021 $413 $471 $158–$1,421 $132
2022 $1,420 $725 $222–$2,183 $149
2023 $1,563 $836 $257–$2,440 $160
2024 $821,081 $909 $252–$2,619 $164
2025 $2,008 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ConvaTec Inc. $817,190 77 payments
  2. Medtronic, Inc. $4,240 55 payments
  3. Philips Electronics North America Corporation $2,740 92 payments
  4. Abbott Laboratories $1,393 30 payments
  5. Endologix, Inc. $1,234 9 payments
  6. Medtronic Vascular, Inc. $1,209 37 payments
  7. W. L. Gore & Associates, Inc. $757 9 payments
  8. Terumo Medical Corporation $561 5 payments
  9. Bard Peripheral Vascular, Inc. $541 5 payments
  10. AngioDynamics, Inc. $279 4 payments
  11. Other $1,648 49 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Debt forgiveness $817,190 77 payments
  2. Food and Beverage $14,602 295 payments
Products named General payments · program years 2019–2025
  1. INNOVAMATRIX AC $817,190 77 payments
  2. ENDURANT IIS $2,837 35 payments
  3. (9281) Turbo Elite $1,119 44 payments
  4. HawkOne Directional Atherectomy Devices $937 13 payments
  5. Ovation $762 5 payments
  6. IGT D Peripheral $622 29 payments
  7. HawkOne Directional Atherectomy Devices $478 23 payments
  8. AFX $472 4 payments
  9. RotarexS 6 F x 135 cm $448 4 payments
  10. Diamondback Peripheral $409 4 payments
  11. Other $6,921 146 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 76 billing codes

Paid by Medicare

$1,935,371

Of which drugs: $2,436

Medicare patients

730

Average age 74

Services billed

23,923

370 women, 360 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 53%
Ischemic heart disease 48%
Chronic kidney disease 42%
Heart failure 35%
Atrial fibrillation 26%
COPD 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 130 19,730 $2,064
Injection, fentanyl citrate, 0.1 mg J3010 Office 112 205 $149
Injection, midazolam hydrochloride, per 1 mg J2250 Office 96 281 $31

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

372 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record